DK3137504T3 - Antistofbinding til fcrn til behandling af autoimmunsygdomme - Google Patents

Antistofbinding til fcrn til behandling af autoimmunsygdomme Download PDF

Info

Publication number
DK3137504T3
DK3137504T3 DK15785500.8T DK15785500T DK3137504T3 DK 3137504 T3 DK3137504 T3 DK 3137504T3 DK 15785500 T DK15785500 T DK 15785500T DK 3137504 T3 DK3137504 T3 DK 3137504T3
Authority
DK
Denmark
Prior art keywords
fcrn
treatment
autoimmune diseases
antibody binding
antibody
Prior art date
Application number
DK15785500.8T
Other languages
English (en)
Inventor
Sung Wuk Kim
Seung Kook Park
Jae Kap Jeong
Hyea Kyung Ahn
Min Sun Kim
Eun Sun Kim
Hae-Young Yong
Dongok Shin
Yeon Jung Song
Tae Hyoung Yoo
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Application granted granted Critical
Publication of DK3137504T3 publication Critical patent/DK3137504T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
DK15785500.8T 2014-04-30 2015-04-30 Antistofbinding til fcrn til behandling af autoimmunsygdomme DK3137504T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
DK3137504T3 true DK3137504T3 (da) 2023-08-14

Family

ID=54358928

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15785500.8T DK3137504T3 (da) 2014-04-30 2015-04-30 Antistofbinding til fcrn til behandling af autoimmunsygdomme

Country Status (21)

Country Link
US (5) US10544226B2 (da)
EP (2) EP3137504B1 (da)
JP (1) JP6449441B2 (da)
KR (2) KR101954906B1 (da)
CN (2) CN106459215B (da)
AU (2) AU2015253915B2 (da)
CA (2) CA3095295C (da)
DK (1) DK3137504T3 (da)
EA (1) EA038470B1 (da)
ES (1) ES2952583T3 (da)
FI (1) FI3137504T3 (da)
HU (1) HUE062403T2 (da)
IL (2) IL248159B (da)
MX (2) MX2016014210A (da)
NZ (2) NZ737666A (da)
PL (1) PL3137504T3 (da)
PT (1) PT3137504T (da)
RS (1) RS64542B1 (da)
SA (1) SA516380194B1 (da)
SG (1) SG11201608208VA (da)
WO (1) WO2015167293A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
ES2864211T3 (es) 2016-04-25 2021-10-13 Syntimmune Inc Anticuerpos anti-FcRn humanizados con maduración de la afinidad
AU2017301915A1 (en) * 2016-07-29 2019-02-28 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
MA49378A (fr) * 2017-06-15 2020-04-22 UCB Biopharma SRL Méthode de traitement de la thrombocytopénie immunitaire
EP3723802A1 (en) 2017-12-13 2020-10-21 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP3876985A1 (en) * 2018-11-06 2021-09-15 Immunovant Sciences GmbH Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2021101975A1 (en) 2019-11-19 2021-05-27 Immunovant Sciences Gmbh Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
TW202140560A (zh) * 2020-02-10 2021-11-01 大陸商北京拓界生物醫藥科技有限公司 抗ＦｃＲｎ抗體、其抗原結合片段及其醫藥用途
MX2023000009A (es) * 2020-06-29 2023-04-03 Hanall Biopharma Co Ltd Formulacion para anticuerpo anti-fcrn.
WO2022031882A1 (en) * 2020-08-06 2022-02-10 Stelexis Therapeutics, Llc Il-8 antibodies and methods of use thereof
CN113484526A (zh) * 2021-08-11 2021-10-08 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
WO2023091920A1 (en) * 2021-11-16 2023-05-25 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
WO2023235679A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
WO2024023271A1 (en) * 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024052358A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
WO2024052357A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Methods of treating graves' disease using anti-fcrn antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
EP1660128A4 (en) 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
EP1986690A4 (en) 2006-01-25 2009-05-13 Univ New York State Res Found ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES
KR101886610B1 (ko) 2007-06-01 2018-08-09 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
TWI547287B (zh) * 2008-04-25 2016-09-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
BR112013030352B1 (pt) * 2011-06-02 2020-05-19 Dyax Corp anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo
KR20130071961A (ko) * 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
PE20190920A1 (es) 2013-04-29 2019-06-26 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodos de utilizacion
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
US20230235063A1 (en) 2023-07-27
HUE062403T2 (hu) 2023-10-28
CA3095295C (en) 2023-01-10
IL248159B (en) 2021-02-28
KR20160145779A (ko) 2016-12-20
RS64542B1 (sr) 2023-09-29
US20200109201A1 (en) 2020-04-09
AU2018203582A1 (en) 2018-06-14
IL280613A (en) 2021-03-25
FI3137504T3 (fi) 2023-08-07
MX2021005193A (es) 2021-09-08
IL248159A0 (en) 2016-11-30
EP4241852A2 (en) 2023-09-13
US11613578B2 (en) 2023-03-28
AU2018203582B2 (en) 2019-05-02
IL280613B (en) 2021-12-01
NZ726089A (en) 2017-12-22
NZ737666A (en) 2018-10-26
EP3137504B1 (en) 2023-05-10
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
MX2016014210A (es) 2017-05-01
JP6449441B2 (ja) 2019-01-09
WO2015167293A1 (en) 2015-11-05
US20240092913A1 (en) 2024-03-21
CN106459215A (zh) 2017-02-22
CA2945086C (en) 2020-12-29
US10544226B2 (en) 2020-01-28
SG11201608208VA (en) 2016-11-29
SA516380194B1 (ar) 2020-10-14
CA2945086A1 (en) 2015-11-05
US20170210801A1 (en) 2017-07-27
CN111138540B (zh) 2023-07-25
CA3095295A1 (en) 2015-11-05
ES2952583T3 (es) 2023-11-02
PL3137504T3 (pl) 2023-10-16
BR112016025319A2 (pt) 2017-12-12
EP3137504A1 (en) 2017-03-08
EA201692192A1 (ru) 2017-04-28
CN106459215B (zh) 2019-12-24
EP4241852A3 (en) 2023-11-15
KR20180093128A (ko) 2018-08-20
EP3137504A4 (en) 2018-02-28
US20190135917A1 (en) 2019-05-09
JP2017522043A (ja) 2017-08-10
CN111138540A (zh) 2020-05-12
AU2015253915A1 (en) 2016-12-01
AU2015253915B2 (en) 2018-05-10
EA038470B1 (ru) 2021-09-01
KR101954906B1 (ko) 2019-03-08

Similar Documents

Publication Publication Date Title
DK3137504T3 (da) Antistofbinding til fcrn til behandling af autoimmunsygdomme
DK3172227T3 (da) Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
KR102355950B9 (ko) Tigit에 대한 항체
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3604527T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3193929T3 (da) Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
DK3221359T3 (da) Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3126395T3 (da) Multispecifikke antistoffer
DK3492632T3 (da) Metoder til behandling af lithiumholdige materialer
DK3301115T3 (da) Kontinuerlig flertrinsfremgangsmåde til oprensning af antistoffer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3242892T3 (da) Modificerede april-bindende antistoffer
DK3468997T3 (da) Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
DK3215530T3 (da) Forbedrede il-6 antistoffer
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3177931T3 (da) Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder